NVO · Novo Nordisk filed a routine 6-K providing a weekly update on its…

Novo Nordisk filed a routine 6-K providing a weekly update on its ongoing DKK 15 billion share repurchase program. There are no new financial results, guidance changes, or material corporate events in this filing.

• Total share repurchase program of up to DKK 15 billion running from 4 Feb 2026 to 3 Feb 2027.
• Since 4 Feb 2026, repurchased 23,984,179 B shares at avg price DKK 272.45 for total DKK 6,534,545,458.
• As of 10 Jul 2026, Novo Nordisk holds 41,169,480 B shares as treasury shares, equal to 0.9% of share capital.
• Under the sub-program started 6 May 2026, up to DKK 11.2 billion in B shares may be repurchased through 1 Feb 2027.